Navigation Links
Preclinical Study Examines Use of nContact's Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
Date:2/23/2012

MORRISVILLE, N.C., Feb. 23, 2012 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, today announced that a new preclinical study examines a unique minimally invasive percutaneous approach to accessing the heart that may enable electrophysiologists (EPs) to perform epicardial ablation for ventricular tachycardia (VT). The study was published in the February 2012 issue of The Journal of Innovations in Cardiac Rhythm Management.

In the study, "Creating Transmural, Linear Epicardial Ablation Lesions via a Non-surgical, Percutaneous, Subxyphoid, Electrogram-guided Approach," researchers sought to modify an existing epicardial ablation device's (nContact's EPi-Sense® Guided Coagulation Device with VisiTrax®) transdiaphragmatic approach to a percutaneous subxyphoid (below the sternum) approach that could enable epicardial ablation without requiring a more invasive surgical access. The EPi-Sense® system has been used clinically in Europe for the treatment of atrial fibrillation and investigators in this study suggest it may also be suitable for the treatment of sinus tachycardia and challenging VT. 

"In this study, we examined for the first time a truly minimally invasive, 'incisionless' approach to performing epicardial ablation. Clinical experience has shown that VT and other arrhythmias originating on the epicardial aspect of the heart may not respond to endocardial ablation, suggesting the need for less invasive tools designed to create lesions on the epicardium," said lead investigator Miguel Valderrabano, MD, FACC of The Methodist Hospital, Houston, TX. "While further studies are needed on the applicability of this technique in clinical electrophysiology, our findings suggest it may expand the capabilities of EP-guided ablation and offer promising clinical utility in addressing VT."

For this preclinical study, researchers performed epicardial ablation on six pigs with a percutaneous subxyphoid puncture access. Under fluoroscopy, a guide wire was advanced through the needle puncture into the pericardial space and the subcutaneous tissue was dilated with an angioplasty balloon, allowing physicians to advance the EPi-Sense® device into the pericardium without endoscopy or surgical tools. Utilizing fluoro imaging and mapping diagnostics, physicians were able to position the device by manipulating the wire, and tissue contact was verified by sensing electrodes embedded in the device's ablation coil. Epicardial ablation was then performed on both atria and both ventricles, with explanted hearts confirming the accuracy of lesion locations and consistent lesion transmurality.

"We are pleased that our technology is facilitating continued physician innovation in cardiac ablation and potentially opening new avenues for the epicardial treatment of VT," said John Funkhouser, President and CEO of nContact. "We are continuing to innovate and lead the epicardial ablation space with easier  'incisionless' access and sensing capabilities in our device  to allow electrophysiologists to map  the precise location of our device in order to properly position the device on the ventricle."

For more information on nContact's technology, please visit www.ncontactinc.com and www.ncontactinc.eu .

About nContact, Inc.
nContact, Inc. is the leading innovator in epicardial ablation devices and techniques. Its mission is to transform the underserved arrhythmia market through the advancement of less invasive, more efficacious ablation alternatives for cardiac arrhythmias. Its lead technologies, the EPi-Sense® and Numeris® Coagulation System with VisiTrax®, have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

The Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States.  nContact was founded in 2005 and is headquartered in Morrisville, North Carolina, U.S.A.

 Media Contacts

 Beth Rose

Kimberly Muscara nContact, Inc

The Ruth Group T (919)655-1566 

T (646) 536-7011 brose@ncontactinc.com 

kmuscara@theruthgroup.com  

 

 

 


'/>"/>
SOURCE nContact, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):